The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant gemcitabine, docetaxel, and capecitabine results in comparable surgical outcomes to modified FOLFIRINOX in patients with pancreatic ductal adenocarcinoma who also receive radiation: A single institution experience.
 
Winston Wong
No Relationships to Disclose
 
Jacob K.R. Jamison
No Relationships to Disclose
 
Michael S. May
No Relationships to Disclose
 
Alissa Michel
No Relationships to Disclose
 
Tristan Lee
No Relationships to Disclose
 
David Manrique
No Relationships to Disclose
 
Alexander Raufi
No Relationships to Disclose
 
Samuel M Pan
No Relationships to Disclose
 
Rachael A Safyan
No Relationships to Disclose
 
David Paul Horowitz
No Relationships to Disclose
 
Beth Schrope
No Relationships to Disclose
 
Michael Kluger
No Relationships to Disclose
 
Lisa A. Kachnic
Consulting or Advisory Role - New B Innovation
Research Funding - Varian Medical Systems
Patents, Royalties, Other Intellectual Property - UpToDate
 
Jianhua Hu
No Relationships to Disclose
 
Susan Elaine Bates
No Relationships to Disclose
 
John A. Chabot
No Relationships to Disclose
 
Gulam Abbas Manji
Stock and Other Ownership Interests - Gilead Sciences
Honoraria - Celgene; Exelixis; Roche/Genentech
Consulting or Advisory Role - BiolineRx; CEND Pharmaceuticals; Exelixis; Ipsen; Roche/Genentech
Research Funding - BiolineRx (Inst); Merck (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Celgene; Exelixis; Roche/Genentech